Drug Trial Radar · NCT07415252
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Jul 4, 2026
Primary completion
Feb 13, 2027
Study completion Jan 2, 2028
Sponsor
- Lead sponsor
- SK Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years. Participants will be randomly assigned to receive either the investigational vaccine (NBP608) or licensed varicella vaccines. Participants will: Receive two subcutaneous injections of a study vaccine administered. Visit the study clinic seven times over approximately 15 months. Receive follow-up phone calls 7 days after each vaccination to monitor for safety.
Conditions
- Varicella (Chickenpox)
Interventions
NBP608 (Mid Potency)Biological
NBP608 (mid potency) is a live attenuated varicella virus vaccine (Oka/SK strain).
NBP608 (Low Potency)Biological
NBP608 (low potency) is a live attenuated varicella virus vaccine (Oka/SK strain).
Varivax®Biological
Varivax® is a licensed live attenuated varicella virus vaccine (Oka/Merck strain).
SKYVaricella®Biological
SKYVaricella® is a licensed live attenuated varicella virus vaccine (Oka/SK strain).
Normal Saline (Placebo)Other
Placebo consisting of normal saline (0.9% sodium chloride solution).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate of varicella-zoster virus(VZV)Time frame: 6 weeks after each dose.
- Geometric mean antibody titer (GMT) of varicella-zoster virus(VZV) IgG antibodiesTime frame: 6 weeks after the second dose.
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
San Pedro Sula, site 101
San Pedro Sula, Cortés Department, Honduras · Not yet recruiting
Tegucigalpa, site 102
Tegucigalpa, Francisco Morazán Department, Honduras · Recruiting
Manila, site 301
Manila, National Capital Region, Philippines · Recruiting
Quezon City, site 302
Quezon City, National Capital Region, Philippines · Recruiting
Quezon City, site 303
Quezon City, National Capital Region, Philippines · Recruiting
Daegu, site 404
Daegu, Daegu, South Korea · Recruiting
Ansan, site 401
Ansan, Gyeonggi-do, South Korea · Recruiting
Hwaseong-si, site 406
Hwaseong-si, Gyeonggi-do, South Korea · Not yet recruiting
Seongnam-sit, site 405
Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting
Incheon, site 403
Incheon, Incheon, South Korea · Recruiting
Seoul, site 402
Seoul, Seoul, South Korea · Recruiting
Seoul, site 408
Seoul, Seoul, South Korea · Not yet recruiting
Seoul, site 407
Seoul, Seoul, South Korea · Not yet recruiting
Khon Kaen City, site 201
Khon Kaen, Changwat Khon Kaen, Thailand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.